targeted therapyVHL gene alterationsplasma markersprognostic valueтаргетная терапияальтерации гена VHLплазменные маркерыпрогностическая значимость1.1. Wood C.G. Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. Clin Cancer Res 2007; 13(Suppl 2):697−702.Wood C.G. Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. Clin Cancer Res 2007; 13(Suppl 2):697−702.2.2. Херрингтон С., Макги Дж. Молекулярная клиническая диагностика. Пер. с англ. М.: Мир,1999. 558 с.Херрингтон С., Макги Дж. Молекулярная клиническая диагностика. Пер. с англ. М.: Мир,1999. 558 с.3.3. Hansel D.E., Rini B.I. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Reviews in Anticancer Therapy 2008; 8:895−905.Hansel D.E., Rini B.I. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Reviews in Anticancer Therapy 2008; 8:895−905.4.4. Linehan W.M., Walther M.M., Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163−72.Linehan W.M., Walther M.M., Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163−72.5.5. Linehan W.M., Zbar B., Klausner R.D. The genetic basis of human cancer, chapter 27 (Renal carcinoma). 2nd ed. USA.: McGraw-Hill Companies, 2002.Linehan W.M., Zbar B., Klausner R.D. The genetic basis of human cancer, chapter 27 (Renal carcinoma). 2nd ed. USA.: McGraw-Hill Companies, 2002.6.6. Smits K.M., Schouten L.J., Dijk B.A. et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008;14:782−7.Smits K.M., Schouten L.J., Dijk B.A. et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008;14:782−7.7.7. Gallou C., Joly D., Mejean A. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999; 13: 464–75.Gallou C., Joly D., Mejean A. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999; 13: 464–75.8.8. Choueiri T.K., Vaziri S.A.J., Jaeger E. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180(3):860−5.Choueiri T.K., Vaziri S.A.J., Jaeger E. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180(3):860−5.9.9. Rini B.I., Jaeger E., Weinberg V. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU International. 2006 Oct 1; 98(4):756−62.Rini B.I., Jaeger E., Weinberg V. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU International. 2006 Oct 1; 98(4):756−62.10.10. Hutson T., Davis I.D., Macheils J.H. et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26.Hutson T., Davis I.D., Macheils J.H. et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26.11.11. Kim J.H., Jung C.W., Cho Y.H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005;13: 859−64.Kim J.H., Jung C.W., Cho Y.H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005;13: 859−64.12.12. Van Houwelingen K.P., van Dijk B.A., Hulsbergen-van de Kaa C.A. et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results fromTheNetherlands Cohort Study. BMCCancer 2005;5:57.Van Houwelingen K.P., van Dijk B.A., Hulsbergen-van de Kaa C.A. et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results fromTheNetherlands Cohort Study. BMCCancer 2005;5:57.13.13. Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6):669−76.Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6):669−76.14.14. Rioux-Leclercq N., Fergelot P., Zerrouki S. et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38(10):1489−95.Rioux-Leclercq N., Fergelot P., Zerrouki S. et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38(10):1489−95.15.15. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343−7.Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343−7.16.16. Klatte T., Böhm M., Nelius T. et al. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU International. 2007;100(1):209−14.Klatte T., Böhm M., Nelius T. et al. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU International. 2007;100(1):209−14.17.17. Negrier S., Perol D., Menetrier-Caux C. et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6−from the Groupe Francais d’Immunotherapie. J Clin Oncol 2004 Jun 15; 22(12):2371−8.Negrier S., Perol D., Menetrier-Caux C. et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6−from the Groupe Francais d’Immunotherapie. J Clin Oncol 2004 Jun 15; 22(12):2371−8.18.18. Alamdari F.I., Rasmuson T., Grankvist K., Ljungberg B. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scandinavian journal of urology and nephrology 2007;41(1):5−9.Alamdari F.I., Rasmuson T., Grankvist K., Ljungberg B. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scandinavian journal of urology and nephrology 2007;41(1):5−9.19.19. Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51(1):168−73.Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51(1):168−73.20.20. Deprimo S.E., Bello C.L., Smeraglia J. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.Deprimo S.E., Bello C.L., Smeraglia J. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.21.21. Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743−8.Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743−8.22.22. Escudier B., Eisen T., Stadler WM. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312−8.Escudier B., Eisen T., Stadler WM. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312−8.